Clinical trial
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
NCT07215559 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 16, 2025
- Completion date
- May 31, 2027
- Enrollment
- 200 (estimated)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.